Ventyx Shares Soar 86.5% After Hours on Positive Phase 2 Trial Results for Obesity Drug Candidate

Ventyx Biosciences Inc. (VTYX) shares jumped 86.53% to $7.20 in after-hours trading after the company reported positive Phase 2 trial results for its obesity and cardiovascular risk drug candidate, VTX3232. The study showed a 78% reduction in hsCRP levels at week 12 compared to baseline, and VTX3232 was safe and well-tolerated.